Biotin (Vitamin B7)
Biotin is a water-soluble B vitamin; human studies found lower total cholesterol in type 2 diabetes and mixed findings for hair, skin, nails and multiple sclerosis.
We evaluated 123 human studies on Biotin (Vitamin B7), including 12 randomised controlled trials and 6 meta-analyses or systematic reviews; the controlled studies include 1,170 participants in total. As of 11 October 2026.
1. What Is Biotin (Vitamin B7)? Occurrence, Origin and Forms
Biotin is a water-soluble vitamin of the B group. In the body it acts as a coenzyme of several carboxylases involved in fat, carbohydrate and protein metabolism. As a supplement it is traditionally associated with hair, skin and nails, and medically it is given in confirmed biotin deficiency and in inborn disorders of biotin metabolism.
Biotin occurs in many foods, among them egg yolk, liver, nuts, oats, soy and yeast, and is additionally produced by gut bacteria. In body cells it is present bound to protein.
In foods biotin is bound to protein and is released in the gut by the enzyme biotinidase. In supplements it is present in free form; human studies examine free biotin taken by mouth, high-dose biotin and biotin as a component of combination products, and in metabolic medicine also biotin as an infusion.
Forms and Preparations Studied
- Biotin from foods, bound to protein
- Free biotin as a dietary supplement (tablets, capsules, drops)
- High-dose biotin as used in studies of neurological disease
- Biotin in combination products with other vitamins and minerals
- Biotin for injection or infusion in inborn metabolic disorders
Not covered on this page:
- Other B vitamins such as thiamine, riboflavin, pantothenic acid, folate and cobalamin are substances in their own right, even when they occur in the same products.
- Combination products for hair, skin and nails that contain zinc, selenium or amino acids alongside biotin are not studies of biotin alone.
- Interference of laboratory tests by biotin, for instance in immunoassays, is an analytical safety topic and not an area of application.
2. What Does Biotin (Vitamin B7) Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Biotin deficiency | mostly improved | moderate | 0 meta-analyses · 3 controlled · 24 other | 128 |
| Multiple sclerosis | mostly no difference | low | 2 meta-analyses · 2 controlled · 20 other | 247 |
| Hair loss | mixed | unclear | 1 meta-analyses · 2 controlled · 9 other | 165 |
| Skin and skin inflammation | mostly no difference | unclear | 0 meta-analyses · 2 controlled · 5 other | 165 |
| Glucose and lipid metabolism | mixed | unclear | 1 meta-analyses · 1 controlled · 5 other | 40 |
| Brittle nails | mixed | unclear | 0 meta-analyses · 1 controlled · 2 other | 105 |
| Other investigations | mostly no difference | unclear | 0 meta-analyses · 2 controlled · 51 other | 146 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Biotin (Vitamin B7) and Biotin Deficiency: Human Studies
In pregnant women with increased excretion of 3-hydroxyisovaleric acid, a sign of mild biotin deficiency, this decreased with biotin in a randomized trial, while it increased slightly with placebo 15. In children with severe protein-energy malnutrition, the activity of biotin-dependent enzymes in lymphocytes increased with biotin, most strongly in those with initially low levels 20. The evidence is considered moderate, as both studies are small and involve different populations and outcome measures.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 10 Hanson et al. 2026 | randomised controlled · 80 participants | Prenatal multivitamin with 150 µg (intervention) or 30 µg (control) biotin; 150 µg vs. 30 µg biotin daily; 24 weeks; vs. Low-dose biotin (30 µg) in the same multivitamin | Plasma 3HIA-carnitine: improved (p = 0.035) |
| 15 Mock et al. 2002 | randomised controlled · 26 participants | Biotin supplement or placebo; 300 µg (1.2 µmol) biotin per day; 14 days; vs. Placebo-controlled, randomized | Urinary 3-HIA excretion (early pregnancy): improved (decreased (P < 0.006) by 11.7 +/- 3.6 mmol/mol creatinine); Urinary 3-HIA excretion (late pregnancy): improved (decreased (P < 0.002) by 7.1 +/- 1.2 mmol/mol creatinine) |
| 20 Velázquez et al. 1995 | controlled · 22 participants | Biotin supplement; 10 mg/d; vs. Placebo, double-blind | Lymphocyte propionyl CoA carboxylase activity: unclear; Lymphocyte pyruvate carboxylase activity: unclear |
| 22 Jezela-Stanek et al. 2022 | cross-sectional study · 1,071,463 participants | Biotinidase activity in dried blood spot and serum, BTD gene sequencing | Prevalence of biotinidase deficiency (1:66,966 births, while 1:178,577 for profound and 1:107,146 for partial forms) |
| 26 Upadia et al. 2025 | cohort study · 478 participants | Newborn screening for inborn errors of metabolism, including biotinidase deficiency; January 2005 to December 2024 | Incidence of inborn metabolic disorders: unclear (1 in 2574 live births); Most common condition: biotinidase deficiency: unclear |
| 27 Sharma et al. 2024 | cross-sectional study · 407 participants | Biotinidase enzyme analysis and BTD gene sequencing; vs. enzyme activity <10% vs. >10% of mean normal | enzyme activity <10% of mean normal: unclear (36 patients); most common variant in profound deficiency: unclear (c.528G>T); most common variant in activity >10%: unclear (c.1330G>C) |
| 28 Yaralı et al. 2024 | cohort study · 357 participants | Biotin; vs. no control group | biotinidase enzyme activity in homozygous p.D424His mutation: improved (above 30% in 97.3% of patients); prevention of symptoms with biotin treatment: improved (mild symptoms were effectively prevented) |
| 29 Çıkı et al. 2024 | cross-sectional study · 302 participants | Biotin (endogenous, in biotinidase deficiency); vs. genotype-phenotype correlation, no intervention comparison | genotype-phenotype association in biotinidase deficiency: unclear |
Further studies in this area: 30 35 41 45 49 50 52 61 62 65 77 79 83 84 86 91 99 103 107
Biotin (Vitamin B7) and Multiple Sclerosis: Human Studies
In multiple sclerosis, high-dose biotin (MD1003) has been tested against placebo in several randomized trials 7925. In a randomized trial in progressive MS, disability improved in some patients on high-dose biotin, and in none on placebo 7. EDSS progression was also lower 7. The follow-up study SPI2 did not confirm this benefit 25. Another randomized controlled trial showed no difference in visual acuity, retinal nerve fiber layer thickness, and quality of life in MS-related chronic vision loss 9. A systematic review with meta-analysis found no confirmed difference from placebo in disability and EDSS, but more often a faster walking time 1. The certainty of evidence is low: the first study showed benefit in some patients, but the follow-up study and the meta-analysis did not confirm this for disability. It remains open whether a subgroup benefits, for example in walking ability.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Espiritu et al. 2021 | meta-analysis · 889 participants | High-dose biotin (MD1003), oral, as adjunctive treatment; at least 300 mg/day; 12 to 15 months; vs. Placebo | Composite improvement of MS-related disability: no difference (RR 2.87; 95% CI 0.29-28.40); Improvement in expanded disability status scale: no difference (RR 2.27; 95% CI 0.25-20.98); Improvement in EDSS and 25-foot walk time: no difference (RR 0.58; 95% CI 0.17-2.00) |
| 5 Marx et al. 2020 | systematic review | Biotin as nutraceutical; vs. Control | Biological and/or clinical outcomes: unclear (1/2) |
| 7 Tourbah et al. 2016 | randomised controlled · 154 participants | MD1003 (high-dose biotin); 100 mg biotin thrice daily; 12 months double-blind, then 12 months open-label for all; vs. Placebo | Proportion with disability reversal (primary endpoint): improved (13 (12.6%) MD1003-treated patients achieved the primary endpoint versus none of the placebo-treated patients (p = 0.005)); EDSS progression: improved; Clinical impression of change: improved |
| 9 Tourbah et al. 2018 | randomised controlled · 93 participants | MD1003 (high-dose pharmaceutical-grade biotin); 300 mg/day orally; 6 months double-blind, then 6 months open-label; vs. Placebo; manufacturer-funded | Mean change in visual acuity (logMAR, 100% contrast) at 6 months: no difference (p = 0.66); 100% contrast VA in PON subgroup: no difference (p = 0.45); logMAR at 5% contrast: no difference |
| 25 Joseph et al. 2026 | study · 506 participants | High-dose biotin vs. placebo (SPI2 trial), arms pooled; Follow-up over 27 months; vs. Pooled treatment arms, no efficacy analysis | Serum NfL and daily step count: improved (IRR = 0.97, p = 0.014); 10% increase in steps and NfL z-score: improved (0.015 decrease in sNfL z-score (95% CI -0.022 to -0.008; p < 0.001)); Prior NfL increases and subsequent step count: unclear (β = -141; 95% CI -302 to 21; p = 0.088) |
| 31 Pape et al. 2020 | cross-sectional study · 186 participants | vitamins and dietary supplements, including biotin; biotin 10 and 300 mg/day in healthy volunteers; vs. biotin intake vs. none; sNfL measurement with/without biotin | frequency of supplement intake: no difference (72.6%); interference of biotin with sNfL measurement: no difference |
| 32 Couloume et al. 2020 | cohort study · 178 participants | High-dose biotin; 12 months; vs. No control group, comparison to baseline | EDSS score improvement: no difference (3.8%); Other disability scales: worsened (increased significantly); Patient-reported stability: no difference (47.4%) |
| 37 Collongues et al. 2021 | cohort study · 48 participants | High-dose pharmaceutical-grade biotin (MD1003); 1 year; vs. No control group, before/after observation | Clinical response (EDSS, 25FWT, 9HPT): improved (13 patients (27%)); Brain volume gain: improved (7/24 patients); Cervical spinal cord volume gain: improved (10/19 patients) |
Further studies in this area: 38 46 80 81 94 95 99 100 104 110 111 112 114 115 116 117
Biotin (Vitamin B7) and Hair Loss: Human Studies
A systematic review found three studies on biotin in hair loss; the most informative, placebo-controlled one showed no difference in hair growth 4. With biotin from a plant extract, with or without silica, hair loss decreased in a placebo-controlled study compared with baseline 8. A hair product for application with Redensyl, saw palmetto and biotin performed better together with platelet-rich plasma than Procapil with platelet-rich plasma 12. Injections with biotin and dexpanthenol from two manufacturers reduced hair loss in both groups; there was no group without biotin 13. In acne patients taking isotretinoin, the proportion of growing hairs increased with additional biotin compared with baseline 18. It remains open whether biotin helps in hair loss mainly in a biotin deficiency.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Yelich et al. 2024 | systematic review | Oral biotin as a hair supplement; vs. Placebo or control groups in the included studies | Hair growth: no difference (no difference between the biotin and placebo groups for hair growth); Hair growth or quality: unclear (neither had striking results in favor of biotin) |
| 8 Patel et al. 2025 | randomised controlled · 105 participants | Botanical extracts with biotin from Sesbania grandiflora, some with silica from Bambusa arundinacea; 1.25 mg biotin orally; biotin-silica group additionally 21.75 mg silica; 90 days; vs. Placebo (Treatment A) | Hair fall: unclear (20.61 ± 14.39 (p < 0.001) in biotin and 15.71 ± 10.8 (p < 0.001) in biotin with silica); Hair growth rate: unclear (0.55 mm/day (p < 0.0001) in biotin and 0.57 mm/day (p < 0.0001) in biotin with silica) |
| 18 Aksac et al. 2021 | controlled · 60 participants | Biotin 10 mg/day added to isotretinoin; 10 mg/day; 4 months; vs. isotretinoin alone (group A) vs. isotretinoin plus biotin (group B) | anagen hair ratio: unclear (P = 0.034); telogen hair ratio: unclear (P = 0.003) |
| 21 Schulpis et al. 2001 | case series | Biotin supplementation; 10 mg/day; 45 days of valproic acid treatment; vs. Healthy controls; three valproic acid dose groups | Alopecia: improved |
| 33 Şen et al. 2021 | cohort study · 156 participants | Biotin 1000 mcg/day; 1000 mcg/day; 3 months (biotin deficiency) or mean 2.5 months (self-initiated); vs. patients with vs. without biotin deficiency | decline in hair loss in biotin deficiency: improved (5 (23%)); decline in hair loss without biotin deficiency: improved (11 (38%)); difference between groups with and without biotin deficiency: no difference (P = .2) |
| 34 Kakunje et al. 2025 | cross-sectional study · 150 participants | Valproate treatment; measurement of serum biotinidase and IL-2; 2-year study period; vs. valproate group vs. control group | frequency of hair loss: worsened (18 (24%) persons of study cohort compared to 2 (2.66%) among the control group); biotinidase activity with vs. without hair loss: no difference (U = 656.000, P ≤ 0.001); IL-2 distribution study vs. control: no difference (U = 3,395.00, P = 0.025) |
| 43 Starace et al. 2021 | case series · 25 participants | biotin alone or with topical minoxidil; vs. no control group, retrospective case series | treatment effectiveness: improved |
| 44 González et al. 2025 | study · 22 participants | Serum WS Biotin, water-soluble form of D-biotin; 3 months daily application; vs. no control group (single-arm, pretest-posttest) | Modified Pull Test (MPT) – reduced hairs: improved (reduced by 43.0% at D30, 56.0% at D60, and 76.1% at D90); Modified Hair Wash Test (MHWT) – vellus hairs (<3 cm): improved (significantly reduced by 90.6% at D30, 67.0% at D60, and 74.8% at D90); MHWT – pulled hairs >3 cm: unclear (significantly diminished by 69.4% at D60 and 60.0% at D90. Contrarily, a significant increase of 227.5% was recorded at D30) |
Further studies in this area: 87 96 102 109
Biotin (Vitamin B7), Skin and Skin Inflammation: Human Studies
In acne patients taking isotretinoin, skin moisture decreased significantly without biotin, but not with additional biotin; a direct group comparison was not reported 18. With biotin from a plant extract, with or without silica, skin elasticity increased from baseline in a placebo-controlled study 8. Both studies are small, one was not randomized, and neither reports a direct comparison with the control group. It remains open whether the effects also occur in individuals with adequate biotin status without concomitant medications.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 8 Patel et al. 2025 | randomised controlled · 105 participants | Botanical extracts with biotin from Sesbania grandiflora, some with silica from Bambusa arundinacea; 1.25 mg biotin orally; biotin-silica group additionally 21.75 mg silica; 90 days; vs. Placebo (Treatment A) | Skin elasticity: unclear (0.15 ± 0.06 (p < 0.0001) in biotin and 0.17 ± 0.12 (p < 0.0001) in biotin with the silica group) |
| 18 Aksac et al. 2021 | controlled · 60 participants | Biotin 10 mg/day added to isotretinoin; 10 mg/day; 4 months; vs. isotretinoin alone (group A) vs. isotretinoin plus biotin (group B) | skin hydration: unclear (P = 0.43); skin sebum: no difference; skin retraction: no difference |
| 21 Schulpis et al. 2001 | case series | Biotin supplementation; 10 mg/day; 45 days of valproic acid treatment; vs. Healthy controls; three valproic acid dose groups | Seborrheic rash: improved |
| 52 Ting et al. 2025 | case series · 5 participants | Biotin supplementation; 10-30 mg daily; vs. no control group | Skin rashes: unclear (All patients had skin rashes) |
| 59 Pi et al. 2025 | case series · 2 participants | Oral multivitamin regimen with biotin, lipoic acid, and pantothenic acid; vs. No control group; before-and-after course in patient 2 | Skin lesions on the fingers: improved (resolution of skin lesions on the fingers) |
| 86 Yılmaz et al. 2024 | cross-sectional study | Biotinidase enzyme activity and BTD gene analysis; vs. genotype-phenotype correlations, no treatment groups | genotype-phenotype correlation cutaneous symptoms: unclear (The c.1270G > C variant was most common in patients with cutaneous symptoms) |
| 108 Januszewski et al. 2023 | review | Biotin among 13 other nutritional supplements | Photoprotective effect: improved; Inflammatory skin diseases (atopic dermatitis, psoriasis): improved |
Biotin (Vitamin B7), Glucose and Lipid Metabolism: Human Studies
In adults with type 2 diabetes, total cholesterol fell with biotin in a meta-analysis; the reduction in fasting blood glucose and triglycerides was not statistically confirmed, insulin remained unchanged 2. For mixtures of biotin and chromium picolinate, two randomized controlled studies reported improvements in blood glucose and lipid values in type 2 diabetes, but these findings apply to the mixture and not to biotin alone 614. In the meta-analysis, only the reduction in total cholesterol is confirmed; whether biotin alone lowers blood glucose must be clarified by larger studies.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Zhang et al. 2022 | meta-analysis · 445 participants | Biotin supplementation; 28 to 90 days; vs. Control groups of included RCTs | Fasting blood glucose: no difference (MD: -1.21 mmol/L, 95% CI: -2.73 to 0.31); Total cholesterol: improved (MD: -0.22 mmol/L, 95% CI: -0.25 to -0.19); Triglycerides: no difference (MD: -0.59 mmol/L, 95% CI: -1.21 to 0.03) |
| 3 Chai et al. 2025 | systematic review | Water-soluble vitamins, including biotin | Glycemic control and insulin resistance: unclear |
| 19 Marshall et al. 1980 | controlled · 40 participants | Biotin supplementation; 0.9 mg/day; 71 days; vs. Placebo | Total plasma lipids: unclear (small but statistically significant positive changes); Total plasma phospholipids: unclear (small but statistically significant positive changes); Alpha + beta lipoprotein cholesterol: unclear (small but statistically significant positive changes) |
| 24 Belda et al. 2022 | study · 1,545 participants | Biotin plus fructo-oligosaccharides (prebiotics); vs. high-fat diet-fed mice without supplementation | weight gain and glycaemic deterioration: improved (limiting weight gain and glycaemic deterioration) |
| 66 Walimbe et al. 2025 | case report · 1 participants | Targeted replacement with biotin, lipoic acid and pantothenic acid | Metabolic control: improved |
| 92 Güder et al. 2023 | cross-sectional study | biotin (level measurement, no supplementation); vs. no control group, correlations | biotin levels and cholesterol/triglyceride ratio: unclear (r=0.314); biotin levels and triglyceride levels: unclear (r=-0.315) |
| 98 Mehta et al. 2026 | review | Biotin and/or chromium supplements; vs. Single versus combined supplementation, controls (qualitative) | Fasting blood glucose, HbA1c, insulin resistance: improved (modest but significant improvements); Lipid parameters: improved (modest but significant improvements); Oxidative stress markers: improved (improve oxidative stress markers) |
Biotin (Vitamin B7) and Brittle Nails: Human Studies
With biotin from a plant extract, with or without silica, nail roughness decreased from baseline in a placebo-controlled study with 105 participants 8. A review names biotin alongside collagen peptides, keratin, MSM, and orthosilicic acid among substances that may improve the appearance, strength, and brittleness of nails 105. The certainty of evidence is unclear because only one controlled study is available, which does not report a comparison with placebo, and it remains open whether the participants had a biotin deficiency.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 8 Patel et al. 2025 | randomised controlled · 105 participants | Botanical extracts with biotin from Sesbania grandiflora, some with silica from Bambusa arundinacea; 1.25 mg biotin orally; biotin-silica group additionally 21.75 mg silica; 90 days; vs. Placebo (Treatment A) | Nail roughness: unclear (0.09 ± 0.29 (p < 0.0001) in biotin and 0.06 ± 0.25 (p < 0.0001) in biotin with silica) |
| 97 Fernández-Campos et al. 2020 | study | Regenail® nail lacquer with biotin, MSM, dimethylsilanediol salicylate; vs. Betalfatrus® reference product | Reduction in nail alterations (Beau's lines, onychorrhexis): improved; Reduction in surface roughness: improved; Biotin absorption in hooves: improved |
| 105 Zaraa et al. 2025 | review | Biotin (dietary supplement) | clinical appearance, strength and brittleness of nails: improved |
Biotin (Vitamin B7): Further Outcomes in Studies
In children with asthma, biotin in addition to standard therapy reduced the inflammatory markers TNF-α and 8-OHdG more than placebo; lung function improved only with L-carnitine 11. The other works in this area are predominantly observational studies or investigate biotin in combination products; controlled studies on clinical endpoints are still pending here.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Espiritu et al. 2021 | meta-analysis · 889 participants | High-dose biotin (MD1003), oral, as adjunctive treatment; at least 300 mg/day; 12 to 15 months; vs. Placebo | Incidence of any adverse events (RR 0.98; 95% CI 0.92-1.04); Any serious adverse events (RR 0.98; 95% CI 0.77-1.24); Laboratory test interference (31 patients (4.7%)) |
| 10 Hanson et al. 2026 | randomised controlled · 80 participants | Prenatal multivitamin with 150 µg (intervention) or 30 µg (control) biotin; 150 µg vs. 30 µg biotin daily; 24 weeks; vs. Low-dose biotin (30 µg) in the same multivitamin | Maternal cortisol: improved (p = 0.04); Association biotin–cortisol (maternal and cord blood): unclear (p < 0.05); Association biotin–osteocalcin in cord blood: unclear (β = 0.013, p = 0.044) |
| 11 Khedr et al. 2026 | randomised controlled · 66 participants | Biotin 5 mg capsules twice daily plus standard therapy; 5 mg twice daily; 3 months; vs. Placebo plus standard therapy | Serum TNF-α: improved (P = 0.008); Serum 8-OHdG: improved (P = 0.012); Serum TGF-β1: no difference (P = 0.028) |
| 23 Kong et al. 2025 | cohort study · 144,439 participants | Dietary biotin intake (24-h Oxford WebQ); median 14.06 years follow-up; vs. Q1 (lowest intake) vs. Q2-Q4 | risk of anxiety or depression: improved (HR: 0.86 [0.82, 0.91] for Q2; HR: 0.84 [0.79, 0.88] for Q3; HR: 0.86 [0.81, 0.91] for Q4); dose-response relationship (RCS): improved (approximately "L-shaped") |
| 24 Belda et al. 2022 | study · 1,545 participants | Biotin plus fructo-oligosaccharides (prebiotics); vs. high-fat diet-fed mice without supplementation | microbiome diversity and bacterial biotin production: improved (improves not only the microbiome diversity, but also the potential of bacterial production of biotin and B vitamins) |
| 26 Upadia et al. 2025 | cohort study · 478 participants | Newborn screening for inborn errors of metabolism, including biotinidase deficiency; January 2005 to December 2024 | False-positive rate of screening: unclear (0.93%); Deaths: unclear (at least 11 patients died); Adverse neurodevelopmental outcomes (45.7%) |
| 36 Jaafar et al. 2025 | cross-sectional study · 50 participants | Biotin (serum and follicular fluid levels, no supplementation); vs. Normal, poor, and hyper-responders | Biotin in serum and follicular fluid by ovarian response: no difference; Correlation of follicular biotin with AMH: unclear (p = 0.033); Correlation of follicular biotin with BMI: unclear (p = 0.022) |
| 39 Saudubray et al. 1984 | case series · 41 participants | Vitamin mixture with biotin, thiamine, B12, riboflavin; biotin 10 mg; vs. comparison with similar reported cases | vitamin responsiveness in neonatal defects: unclear (very rarely vitamin responsive) |
Further studies in this area: 40 42 47 48 51 52 53 54 55 56 57 58 59 60 63 64 66 67 68 69 70 71 72 73 74 75 76 77 78 82 85 86 88 89 90 91 92 93 99 100 101 106 107 113 118
4. How Is Biotin (Vitamin B7) Dosed? Preparation, Dose and Duration in Studies
The studies mostly used oral biotin: as a dietary supplement, high-dose as a drug (MD1003) in multiple sclerosis or in combination products with other vitamins, minerals or plant extracts. Biotin was injected together with dexpanthenol in hair loss 13, applied in a hair product with Redensyl and saw palmetto 12. The doses and dosage forms are listed in the table.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Chromium picolinate plus biotin (CPB) | 600 µg chromium and 2 mg biotin once daily | 90 days | 6 |
| MD1003 (high-dose biotin) | 100 mg biotin thrice daily | 12 months double-blind, then 12 months open-label for all | 7 |
| Botanical extracts with biotin from Sesbania grandiflora, some with silica from Bambusa arundinacea | 1.25 mg biotin orally; biotin-silica group additionally 21.75 mg silica | 90 days | 8 |
| MD1003 (high-dose pharmaceutical-grade biotin) | 300 mg/day orally | 6 months double-blind, then 6 months open-label | 9 |
| Prenatal multivitamin with 150 µg (intervention) or 30 µg (control) biotin | 150 µg vs. 30 µg biotin daily | 24 weeks | 10 |
| Biotin 5 mg capsules twice daily plus standard therapy | 5 mg twice daily | 3 months | 11 |
| Topical redensyl, saw palmetto, and biotin plus PRP | — | four sessions at three-week intervals | 12 |
| Weekly injections of biotin 5 mg/1 ml plus dexpanthenol 250 mg/2 ml | Biotin 5 mg plus dexpanthenol 250 mg weekly | 6 weeks treatment, follow-up at 1 and 8 weeks | 13 |
| Chromium picolinate and biotin (CPB) or placebo | — | 4 weeks | 14 |
| Biotin supplement or placebo | 300 µg (1.2 µmol) biotin per day | 14 days | 15 |
| SPP1 specialized food product with biotin and other vitamins | 2 portions of SPP1 per day | 14 days | 16 |
| AG1, comprehensive nutritional supplement with vitamins, minerals, probiotics, phytochemicals | Single serving 13 g mixed in water | Single dose, 1-week washout | 17 |
| Biotin 10 mg/day added to isotretinoin | 10 mg/day | 4 months | 18 |
| Biotin supplementation | 0.9 mg/day | 71 days | 19 |
| Biotin supplement | 10 mg/d | — | 20 |
5. Is Biotin (Vitamin B7) Safe? Side Effects in Studies
Adverse events with high-dose biotin in multiple sclerosis occurred no more frequently than with placebo 179; in children with asthma, biotin proved to be safe 11. However, high-dose biotin distorted laboratory tests in some of those treated, and in no one with placebo 1.
| Study | Reported side effects |
|---|---|
| 1 Espiritu et al. 2021 | Any and serious AEs not different; laboratory test interference in 4.7% on biotin |
| 6 Albarracin et al. 2007 | well tolerated, no adverse effects, similar to placebo |
| 7 Tourbah et al. 2016 | Safety profile similar to placebo |
| 8 Patel et al. 2025 | No adverse events reported |
| 9 Tourbah et al. 2018 | Safety profile similar to placebo |
| 11 Khedr et al. 2026 | Biotin was safe |
| 13 Samadi et al. 2022 | Adverse drug reactions recorded; treatment described as safe |
| 14 Geohas et al. 2007 | No significant adverse events in either group |
| 16 2021 | Product well tolerated |
| 17 Sapp et al. 2026 | Both well tolerated, no serious adverse events |
| 18 Aksac et al. 2021 | biotin prevented mucocutaneous adverse effects of isotretinoin |
| 21 Schulpis et al. 2001 | Skin lesions (seborrheic rash, alopecia) improved with biotin |
6. What Remains Open: Limits of the Evidence
- Most controlled studies are small and short; large long-term studies are still pending.
- Whether the findings for hair, skin and nails are tied to a biotin deficiency is an open question.
- Many findings come from combination products and apply to the mixture, not to biotin alone.
- In multiple sclerosis, the results are inconsistent and only some of the endpoints were investigated.
- For most uses, controlled studies with clinical endpoints are still pending.
7. Bottom Line: What Is Established About Biotin (Vitamin B7)
Biotin is a water-soluble B vitamin that, as a coenzyme of several carboxylases, is involved in fat, carbohydrate and protein metabolism. In type 2 diabetes, biotin lowered total cholesterol in a meta-analysis; the effect on blood glucose is not yet confirmed. For hair, skin and nails, measured values improved in small studies mainly compared with baseline; the most informative placebo-controlled hair study found no difference. Many positive results come from combination products and therefore do not apply to biotin alone. In progressive multiple sclerosis, high-dose biotin showed benefit in an initial study, and the follow-up study did not confirm it. In signs of biotin deficiency, such as in pregnancy, biotin improved biotin-dependent metabolic values. Biotin was well tolerated; in high doses it can distort laboratory tests.
Frequently Asked Questions
How well has Biotin (Vitamin B7) been studied in humans?
We evaluated 123 human studies on Biotin (Vitamin B7), including 12 randomised controlled trials and 6 meta-analyses or systematic reviews; the controlled studies include 1,170 participants in total. As of 11 October 2026.
Does Biotin (Vitamin B7) help with biotin deficiency? What the studies show
Does Biotin (Vitamin B7) help with multiple sclerosis? What the studies show
Does Biotin (Vitamin B7) help with hair loss? What the studies show
Does Biotin (Vitamin B7) help with skin and skin inflammation? What the studies show
Does Biotin (Vitamin B7) help with glucose and lipid metabolism? What the studies show
Does Biotin (Vitamin B7) help with brittle nails? What the studies show
What is biotin and what is it needed for in the body?
Biotin is a water-soluble vitamin from the group of B vitamins. In the body it acts as a coenzyme of several carboxylases that are involved in fat, carbohydrate and protein metabolism. Medically it is given in confirmed biotin deficiency and in congenital disorders of biotin metabolism.
Do human studies show an effect of biotin on hair loss?
A systematic review found three studies on biotin in hair loss; the most informative, placebo-controlled one showed no difference in hair growth 4. For biotin from a plant extract and for combination products with biotin, improvements were reported, but only compared with baseline or another hair product 81213.
How does biotin affect blood glucose and lipid metabolism?
In adults with type 2 diabetes, total cholesterol fell with biotin in a meta-analysis; the reduction in fasting blood glucose and triglycerides was not statistically confirmed, insulin remained unchanged 2. For mixtures of biotin and chromium picolinate, two randomized controlled studies reported improvements in blood glucose and lipid values, but these findings apply to the mixture and not to biotin alone 614.
What role does biotin play in multiple sclerosis?
In multiple sclerosis, high-dose biotin (MD1003) was tested against placebo in several randomized studies 7925. In a randomized study in progressive MS, disability regressed in some patients with high-dose biotin, and in no one with placebo 7. The follow-up study SPI2 did not confirm this benefit 25. Another randomized controlled study showed no difference in visual acuity, nerve fiber layer thickness and quality of life in MS-related chronic vision loss 9. A systematic review with meta-analysis found no confirmed difference from placebo in disability and EDSS, but more often a faster walking time 1.
Is biotin safe and what side effects are known?
Sources
- 1Espiritu AI, Remalante-Rayco PPM · 2021
- 2Zhang Y, Ding Y, Fan Y, Xu Y, Lu Y, Zhai L et al. · 2022
- 3Chai Y, Chen C, Yin X, Wang X, Yu W, Pan H et al. · 2025
- 4Biotin for Hair Loss: Teasing Out the EvidenceYelich A, Jenkins H, Holt S, Miller R · 2024
- 5Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, van der Mei I et al. · 2020
- 6Albarracin C, Fuqua B, Geohas J, Juturu V, Finch MR, Komorowski JR · 2007
- 7Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S et al. · 2016
- 8
- 9Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C et al. · 2018
- 10Hanson I, Draicchio F, Sharafi M, Grier-Welch A, Vance A, Alamdari N et al. · 2026
- 11Khedr MO, El-Haggar SM, El-Razik AMA, elmeazawy RZ, Mostafa TM · 2026
- 12
- 13Samadi A, Ketabi Y, Firooz R, Firooz A · 2022
- 14Geohas J, Daly A, Juturu V, Finch M, Komorowski JR · 2007
- 15Mock DM, Quirk JG, Mock NI · 2002
- 16New Specialized Food Product “SPP1” in Combination With Iso-Calorie Diet Shows Better Efficacy Than the Diet Alone in Treatment of Non-alcoholic Steatohepatitis· 2021
- 17Sapp PA, Townsend JR, Kirby TO, Edwards CG, La Monica MB, Ziegenfuss TN et al. · 2026
- 18Aksac SE, Bilgili SG, Yavuz GO, Yavuz IH, Aksac M, Karadag AS · 2021
- 19Effects of biotin on lipids and other constituents of plasma of healthy men and womenMarshall MW, Kliman PG, Washington VA, Mackin JF, Weinland BT · 1980
- 20Velázquez A, Terán M, Báez A, Gutiérrez J, Rodríguez R · 1995
- 21Schulpis KH, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S · 2001
- 22Jezela-Stanek A, Suchoń L, Sobczyńska-Tomaszewska A, Czerska K, Kuśmierska K, Taybert J et al. · 2022
- 23Kong Y, Xia W, Wang T, Zhang D · 2025
- 24Belda E, Voland L, Tremaroli V, Falony G, Adriouch S, Assmann KE et al. · 2022
- 25Joseph GB, McCune M, Bove R, Abdelhak A, Cree BAC, Block VJ · 2026
- 26Upadia J, Noh G, Crivelly K, Aziz E, Cunningham A, Andersson HC · 2025
- 27Sharma R, Kucera CR, Nery CR, Lacbawan FL, Salazar D, Tanpaiboon P · 2024
- 28Yaralı O, Arslan S, Gündoğdu Öğütlü ÖB, Guler MC, Akgül BN · 2024
- 29Çıkı K, Alavanda C, Ceylan Eİ, Tanyalçın T, Kılavuz S · 2024
- 30Gülbahçe A, Muderrisoglu A, Güneş H, Erdoğan M, Dündar M, Kardaş F · 2026
- 31Pape K, Steffen F, Zipp F, Bittner S · 2020
- 32Couloume L, Barbin L, Leray E, Wiertlewski S, Le Page E, Kerbrat A et al. · 2020
- 33Şen O, Türkçapar AG · 2021
- 34Kakunje A, Prabhu A, Karkal R, Pookoth KR, Kumar P, Gupta N et al. · 2025
- 35Akgun A, Sen A, Onal H · 2021
- 36Jaafar ZAA, Bakir NA, Salman DA · 2025
- 37Collongues N, Kuhle J, Tsagkas C, Lamy J, Meyer N, Barro C et al. · 2021
- 38Birnbaum G, Stulc J · 2017
- 39Saudubray JM, Ogier H, Charpentier C, Depondt E, Coudé FX, Munnich A et al. · 1984
- 40Mohammed M, El Agouza I, Zaitoun R, Ahmad K, Mohammad S, Sallam O et al. · 2026
- 41Ortolano R, Menabò S, Candela E, Biasucci G, Bortolamedi E, Montanari G et al. · 2025
- 42Himmelreich N, Garbade SF, Okun JG, Hengst S, Geiger V, Barone R et al. · 2026
- 43Starace M, Gurioli C, Carpanese MA, Bruni F, Piraccini BM, Patrizi A et al. · 2021
- 44González Fernández D, Duchi S, Fernández Gómez L, León Sala T, Hajuj A, Molho D et al. · 2025
- 45Mock DM, Henrich-Shell CL, Carnell N, Stumbo P, Mock NI · 2004
- 46Guillevin C, Agius P, Naudin M, Herpe G, Ragot S, Maubeuge N et al. · 2019
- 47Créange A, Hutin E, Sedel F, Le Vigouroux L, Lefaucheur JP · 2023
- 48Biswas A, McNamara C, Gowda VK, Gala F, Sudhakar S, Sidpra J et al. · 2023
- 49Moatter T, Ahmed S, Majid H, Jafri L, Bilal M, Najumuddin et al. · 2024
- 50Stratton SL, Bogusiewicz A, Mock MM, Mock NI, Wells AM, Mock DM · 2006
- 51Seilanian Toosi F, Saberifar M, Ahangari N, Hashemi N, Beiraghi Toosi M · 2026
- 52Ting SL, Yakob Y, Sani HA, Rethanavelu K, Ngu LH · 2025
- 53Frankel R, Verscaj C, Tise CG, Cusmano-Ozog K · 2025
- 54Mansour-Hendili L, Gitiaux C, Harion M, Latouche C, Heron B, Stojkovic T et al. · 2024
- 55Ortigoza-Escobar JD, Serrano M, Molero M, Oyarzabal A, Rebollo M, Muchart J et al. · 2014
- 56Raha SJ, Saini AG, Attri SV, Bhatia V, Didwal G, Suthar R et al. · 2026
- 57Atypical presentation of biotinidase deficiency: masquerading neuromyelitis optica spectrum disorderAli F, Mukhtiar K, Raza M, Ibrahim S · 2024
- 58Montomoli M, Vetro A, Tubili F, Donati MA, Daniotti M, Pochiero F et al. · 2023
- 59Pi BK, Lee AJ, Nam SH, Chung KW, Choi BO · 2025
- 60Greenway FL, Ingram DK, Ravussin E, Hausmann M, Smith SR, Cox L et al. · 2011
- 61Rehman T, Saeed R, Rauf MAA, Asif L, Junaid M, Khalid M et al. · 2026
- 62Sharma R, Bhatti A, Singh D, Kapoor N, Bharathiraja S, Kaul S et al. · 2026
- 63Elbarky A, El Amrousy D, Mahmoud S, Lotfy A, Aboeisa M, Elballat KE et al. · 2026
- 64Ahmad QT, Haseeb A, Ullah W, Samad M, Afridi A · 2026
- 65Cao AA, Brown MM, Lee MS, Rashidi AM, Rashidi V · 2025
- 66Walimbe AS, Waskow E, Mackay L, Miller M, Gijavanekar C, Difalco CR et al. · 2025
- 67Kaya Ç, Heydari A, Kızılay O, Kızılay O, Sezgin G · 2025
- 68Ogawa E, Kosaki K, Takenouchi T · 2025
- 69Ren Y, Dang H, Fu Y, Liu C, Li J, Cai J · 2025
- 70Gowda VK, Badrinath AC, Srinivasan VM, Verma MP, Nayyer A · 2025
- 71Tse J, Abu-Qamar A, Youssef O, Pejka SL · 2025
- 72
- 73Van Vyve FX, Mercier N, Papadopoulos J, Heijmans C, Dessy H, Monestier O et al. · 2024
- 74Chodnicki KD, Aksamit AJ, Gavrilova RH, Farnsworth PJ, McClelland CM · 2024
- 75Kim SW, Lee HJ, Choi N, Kim EK, Ko JM · 2024
- 76Abdi F, Parvin S, Zare Hosseinabadi V, Kachuei M, Gordiz A, Hemmati S et al. · 2024
- 77Gowda VK, Avaragollapuravarga Mathada A, Srinivasan VM, Vamyanmane DK · 2023
- 78Aldosari AN, Arisha A, Ibrahim A, Gongi M · 2023
- 79Geng J, Sun Y, Zhao Y, Xiong W, Zhong M, Zhang Y et al. · 2021
- 80Demas A, Cochin JP, Hardy C, Vaschalde Y, Bourre B, Labauge P · 2020
- 81Lebrun C, Cohen M, Mondot L, Ayrignac X, Labauge P · 2017
- 82Ünlü Torlak E, Koç Yekedüz M, Bülbül YE, Kara İS, Erdoğan Kablan S, Eylem CC et al. · 2026
- 83Toledo-Pacheco C, Montero-Hernández M, López-Garrido MP, de Diego-Boguñá C, Sánchez-Sánchez F · 2026
- 84Zioudi A, Benrhouma H, Jamoussi M, Ben Younes T, Miladi Z, Klaa H et al. · 2025
- 85Shrestha B, Karn V, Regmi N, Aryal S, Khadka A, Neupane S · 2025
- 86Yılmaz B, Ceylan AC, Gündüz M, Ünal Uzun Ö, Küçükcongar Yavaş A, Bilginer Gürbüz B et al. · 2024
- 87Durusu Turkoglu IN, Turkoglu AK, Soylu S, Gencer G, Duman R · 2024
- 88Nelson AT, Jones PM, Cao J · 2024
- 89Karataş G, Çakır A, Çakar NE, Çepni Çakır D, Karataş ME, Akpunar O et al. · 2024
- 90Alizadeh M, Kheirouri S, Keramati M · 2023
- 91Hsieh CH, Lee J, Sung HH, Huang YF, Ding YS, Li CY et al. · 2023
- 92
- 93Hauth I, Waterham HR, Wanders RJA, van der Crabben SN, van Karnebeek CDM · 2022
- 94Mathais S, Moisset X, Pereira B, Taithe F, Ciron J, Labauge P et al. · 2021
- 95Branger P, Parienti JJ, Derache N, Kassis N, Assouad R, Maillart E et al. · 2020
- 96Biotin Deficiency in Telogen Effluvium: Fact or Fiction?Abdel Rahman SH, Mohammed Salem R, Hassan Sabry J · 2020
- 97Fernández-Campos F, Navarro F, Corrales A, Picas J, Pena E, González J et al. · 2020
- 98Mehta M, Saini A, Mehta DK, Das R · 2026
- 99Gunay E, Gezmen-Karadag M · 2026
- 100Aguilera-Méndez A, Aguilera-Manuel K, Saavedra-Molina A, Ríos-Chávez P, Villafaña S, Nieto-Aguilar R et al. · 2026
- 101
- 102Troshina EA, Suplotova LA, Dzgoeva FK, Ruyatkina LA, Gadzhigoroeva AG, Gromova OA et al. · 2026
- 103Biotinidase DeficiencyWoodliff B, Benjamin R, Simpson B · 2025
- 104Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M et al. · 2025
- 105Zaraa I, Richert B · 2025
- 106Chungchunlam SMS, Moughan PJ · 2024
- 107Karachaliou CE, Livaniou E · 2024
- 108Januszewski J, Forma A, Zembala J, Flieger M, Tyczyńska M, Dring JC et al. · 2023
- 109Praharaj SK, Munoli RN, Udupa ST, Vaidyanathan S · 2022
- 110Bisaga GN, Mikhailenko AA, Barsukov IN · 2019
- 111Evans E, Piccio L, Cross AH · 2018
- 112
- 113Mastrangelo M · 2018
- 114
- 115Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL · 2016
- 116Sedel F, Bernard D, Mock DM, Tourbah A · 2016
- 117Intersections of pathways involving biotin and iron relative to therapeutic mechanisms for progressive multiple sclerosisHeidker RM, Emerson MR, LeVine SM · 2016
- 118Biotin-Thiamine-Responsive Basal Ganglia DiseaseTabarki B, Al-Hashem A, Ortigoza-Escobar JD, Alsharhan H, Alfadhel M · 1993
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.